DEMSKI MARTHA J

SEC source: 0001198230-26-000007 · edgardoc.xml · nonDerivative · entry 2

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 12,000

F1 · kind: This transaction reflects the transfer of 12,000 shares of Common Stock from the Reporting Person's individual account to a trust for which the Reporting Person serves as trustee. No sale or other change in beneficial ownership occurred as a result of this transfer.

F2 · price: No consideration was paid or received in connection with this transaction, as it represents a personal transfer of shares between accounts controlled by the Reporting Person, and not an open-market or arms'-length transaction. Accordingly, no price is reported.

F3 · balance_after: The Reporting Person is the trustee of the trust and retains sole voting and investment power over the shares held therein. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if applicable.

F4 · ownership.nature: Represents the total number of shares of Common Stock held by the trust following the reported transaction. This is the first transaction reporting shares beneficially owned indirectly through this trust.

SEC source: 0001198230-26-000007 · edgardoc.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction reflects the transfer of 12,000 shares of Common Stock from the Reporting Person's individual account to a trust for which the Reporting Person serves as trustee. No sale or other change in beneficial ownership occurred as a result of this transfer.

F2 · price: No consideration was paid or received in connection with this transaction, as it represents a personal transfer of shares between accounts controlled by the Reporting Person, and not an open-market or arms'-length transaction. Accordingly, no price is reported.

SEC source: 0001198230-26-000005 · edgardoc.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2036-06-01

F1 · derivative.exercise_date: The number of shares subject to the option shall vest on the first anniversary of the grant date.

SEC source: 0001198230-26-000003 · form4-05292026_100505.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2036-05-27

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001850902-25-000023 · edgardoc.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,000

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2025 and was effected to cover tax obligations in connection with the vesting of the reporting person's director restricted stock units.

SEC source: 0001850902-25-000010 · edgardoc.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,300

F1 · shares: Represents restricted stock units granted on June 17, 2025. Shares subject to the award vest on the first anniversary of the grant date.

SEC source: 0001850902-25-000019 · edgardoc.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,300

Underlying: Common Stock · 54,300 shares

Expires 2026-06-17

F1 · derivative.exercise_date: On June 25, 2025, a Form 4 was filed on behalf of the reporting person that incorrectly identified the type of securities granted to such person on June 17, 2025 as being 54,300 restricted stock units, which were included in Table I. This amended Form 4 is being filed to correct that the securities granted to the reporting person on June 17, 2025 were non-qualified stock options to purchase 54,300 shares of common stock, which were granted under the issuer's director compensation policy. These non-qualified stock options are identified on Table II and will vest on the first anniversary of the date of grant.

SEC source: 0001415889-25-014399 · form4-05232025_050551.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 11

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2034-06-19

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 10

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2033-06-08

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 9

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2032-06-22

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 8

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2031-06-22

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 7

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2030-06-10

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 6

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,000 shares

Expires 2029-06-19

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 5

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,000 shares

Expires 2028-06-19

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 4

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,000 shares

Expires 2027-06-27

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 3

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2025-06-21

F4 · price: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares other than an In the Money Option that is then outstanding and unexercised, whether or not vested, was cancelled at the Effective Time with no consideration payable in respect thereof.

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · derivative · entry 2

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2026-06-23

F3 · price: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001415889-25-011069 · form4-04212025_080428.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Martha J. Demski Trust u/a 10/01/94

Disclosed balance after: 0

F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2 · shares: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time , each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 8

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2032-05-23

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F5 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 7

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-05-23

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F5 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 6

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,770 shares

Expires 2031-05-25

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F4 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 5

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,770

Underlying: Common Stock · 20,770 shares

Expires 2031-05-25

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F4 · derivative.exercise_date: These options vest in twelve equal monthly installments commencing on the grant date of May 26, 2021, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 4

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,000 shares

Expires 2030-05-18

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F3 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 3

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-05-18

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F3 · derivative.exercise_date: The options vest in twelve equal monthly installments commencing on the grant date of May 19, 2020, provided, however, that the options will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 2

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2029-06-10

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001415889-25-004758 · form4-02202025_120224.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2029-06-10

F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.

F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments commencing on the grant date of June 11, 2019, provided, however, that the option will become fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001850902-24-000016 · edgardoc.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F1 · shares: Represents restricted stock units granted on June 26, 2024. Shares subject to the award vest on the first anniversary of the grant date.

SEC source: 0001415889-24-017767 · form4-06212024_030601.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting.

SEC source: 0001415889-24-014372 · form4-05232024_100518.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2024, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001850902-23-000033 · edgardoc.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,683

Underlying: Common Stock · 56,683 shares

Expires 2033-08-31

F1 · derivative.exercise_date: 1/3rd of the original number of shares subject to the option shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in equal monthly installments thereafter over 24 months.

SEC source: 0001209191-23-036312 · doc4.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting.

SEC source: 0001209191-23-031704 · doc4.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-05-22

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2023, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001209191-23-028660 · doc4.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By the Martha J. Demski Trust u/a 10/01/94

Disclosed balance after: 72,055

SEC source: 0001140361-23-010769 · form4.xml · derivative · entry 2

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,630

Underlying: Common Stock · 51,630 shares

Expires 2033-03-06

F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

SEC source: 0001140361-23-010769 · form4.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 56,601

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 17,493 shares of common stock owned by the reporting person.

F3 · ownership.nature: These shares are held in the trust account of the Martha J. Demski Trust U/D/T 10/01/94, for which the reporting person serves as trustee.

SEC source: 0001209191-22-039115 · doc4.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2023 annual stockholder meeting.

SEC source: 0001209191-22-031991 · doc4.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 24, 2022, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

SEC source: 0001209191-22-029782 · doc4.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Martha J. Demski Trust u/a 10/01/94

Disclosed balance after: 54,055

SEC source: 0001140361-22-008672 · form4.xml · derivative · entry 2

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,172

Underlying: Common Stock · 53,172 shares

Expires 2032-03-07

F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

SEC source: 0001140361-22-008672 · form4.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 30,786

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 4,200 shares of common stock owned by the reporting person.

F3 · ownership.nature: These shares are held in the trust account of the Martha J. Demski Trust U/D/T 10/01/94, for which the reporting person serves as trustee.

SEC source: 0001328143-21-000087 · wf-form4_163778807188682.xml · derivative · entry 5

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2031-06-01

F8 · price: $2.89 plus two CVRs per share underlying the stock option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.

SEC source: 0001328143-21-000087 · wf-form4_163778807188682.xml · derivative · entry 4

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2030-06-02

F7 · price: $5.40 plus two CVRs per share underlying the stock option.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.

SEC source: 0001328143-21-000087 · wf-form4_163778807188682.xml · derivative · entry 3

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2029-06-04

F6 · price: $3.30 plus two CVRs per share underlying the stock option.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.

SEC source: 0001328143-21-000087 · wf-form4_163778807188682.xml · nonDerivative · entry 2

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").

F3 · shares: Amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.

F2 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.

SEC source: 0001328143-21-000087 · wf-form4_163778807188682.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Martha J. Demski U/D/T 10/1/1994, Martha J. Demski Trustee

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").

F2 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.

SEC source: 0001209191-21-043345 · doc4.xml · derivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2031-06-22

F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2022 annual stockholder meeting.

SEC source: 0001328143-21-000063 · wf-form4_162318792641400.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax obligations in connection with the vesting of the reporting person's director restricted stock awards.

SEC source: 0001328143-21-000055 · wf-form4_162283758509628.xml · derivative · entry 3

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-01

F2 · derivative.exercise_date: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

SEC source: 0001328143-21-000055 · wf-form4_162283758509628.xml · nonDerivative · entry 1

DEMSKI MARTHA J · CIK 0001198230 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.